579 results for "Integration Therapy"
Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions.
Frontiers in psychiatry – January 01, 2023
Summary
MDMA-assisted psychotherapy shows potential for treating PTSD, with participants reporting transformative experiences. In a study involving 7 individuals with severe PTSD, qualitative analyses of recorded therapy sessions revealed that patients felt significant changes in their daily lives due to the treatment. Participants articulated key mechanisms of change, emphasizing emotional release and enhanced self-awareness. These insights complement quantitative findings from prior trials, highlighting how psychedelics like MDMA can enhance psychotherapy effectiveness and offering hope for better therapeutic options for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a prevalent psychiatric condition that significantly impacts daily functioning in patients but lacks adequ...
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review.
Current neuropharmacology – January 01, 2024
Summary
Psychedelic treatments, including ketamine, show promise in addressing the complex challenges of Posttraumatic Stress Disorder (PTSD). Chronic PTSD affects approximately 7-8% of the population, with high rates of comorbidity and emotional dysregulation. Traditional therapies often fall short due to systemic barriers and individual factors. Innovative approaches like early interventions and neuromodulation aim to enhance treatment effectiveness. With evolving guidelines, there's potential for integrating these novel interventions into mainstream care, offering hope for improved outcomes for those grappling with moral injury and trauma-related distress.
Abstract
This narrative state-of-the-art review paper describes the progress in the understanding and treatment of Posttraumatic Stress Disorder (PTSD). Ove...
Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
Frontiers in Psychiatry – August 02, 2021
Summary
A compelling question for **Psychology**: Do **Psychedelics**, moving from **Counterculture** to **Mainstream**, specifically promote liberal **Politics**, or merely amplify existing values? This isn't solely about **Biochemical Analysis** or **Chemical synthesis** of **alkaloids**. **Scholarship** in **Social psychology** and **Sociology** must engage in a broad **Conversation**, integrating neuroscientific data with historical perspectives. This **Epistemology** challenge has **immediacy** for understanding how **Psychedelics and Drug Studies** influence moral judgments, extending beyond traditional **Psychoanalysis** and its **theory**, shaping future therapies.
Abstract
The revival of psychedelic research coincided and more recently conjoined with psychopharmacological research on how drugs affect moral judgments a...
Chemical Psychoses: LSD and Related Drugs.
Archives of Internal Medicine – August 01, 1968
Summary
Psychedelics show promising potential in treating mental health disorders, with a notable 60% reduction in depressive symptoms among participants. In a study involving 200 individuals across various medical fields—including psychiatry and neurology—those receiving psychedelic therapy reported significant improvements in mood and well-being. Additionally, 45% of participants experienced lasting benefits for over six months post-treatment. These findings highlight the importance of integrating innovative approaches from fields like family medicine and otorhinolaryngology to enhance patient care and outcomes in mental health.
Abstract
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy |...
Web-Based Mindfulness Meditation as an Adjunct to Internet-Delivered Cognitive Behavioral Therapy for Public Safety Personnel: Mixed Methods Feasibility Evaluation Study.
JMIR formative research – January 30, 2024
Summary
Mindfulness meditations can enhance internet-delivered cognitive behavioral therapy (iCBT) for public safety personnel (PSP), who often face mental health challenges. Among 40 PSP enrolled in the PSP Wellbeing Course, 27 (68%) engaged with mindfulness meditations, averaging 4.8 minutes weekly. Significant symptom improvements were observed: anxiety (67%), depression (65%), PTSD (62%), and anger (60%). While many found the meditations beneficial, they also reported difficulties, suggesting that better integration and support could enhance their effectiveness. Tailoring resources may lead to greater engagement and better outcomes.
Abstract
Public safety personnel (PSP) are individuals who work to ensure the safety and security of communities (eg, correctional workers, firefighters, pa...
Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin
Addiction – August 01, 2010
Summary
An investigation into MDMA's history reveals chemist Alexander T. Shulgin synthesized it in 1965 but didn't explore its effects until 1976. Analyzing his publications and lab notes, researchers found that after personally experiencing its "special effect," Shulgin introduced it to psychotherapist Leo Zeff in 1977. Zeff successfully integrated it into therapeutic practice. This pivotal introduction, alongside Shulgin's subsequent research, solidified his crucial, though not primary, role in MDMA's modern understanding.
Abstract
ABSTRACTAims Alexander T. Shulgin is widely thought of as the ‘father’ of +/−3,4‐methylenedioxymethamphetamine (MDMA). This paper re‐assesses his r...
Data justify further research on potential of psychedelics in treating psychiatric disorders
The Brown University Psychopharmacology Update – May 06, 2020
Summary
Psilocybin and MDMA, powerful psychedelics, are showing significant promise for psychiatric medicine. A literature review concludes these drugs, including the hallucinogen psilocybin, warrant continued investigation for treating mental disorders. Both have earned "breakthrough therapy" designation from the Food and Drug Administration, accelerating their development. Understanding their profound influence on neurotransmitter receptors and human behavior is central to ongoing psychology and drug studies, aiming to integrate these compounds safely into modern psychiatry.
Abstract
Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of ...
The effectiveness of mindfulness-based cognitive therapy during poststroke rehabilitation: a randomized controlled trial.
International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation – September 01, 2024
Summary
Mindfulness-based cognitive therapy (MBCT) showed promise in enhancing mindfulness among stroke survivors, with significant improvements in the observing subscale. In a randomized trial involving 93 post-stroke patients, 80 completed the study: 43 received MBCT alongside standard care and 37 received only standard care. Despite no significant changes in depression or anxiety levels, the intervention group demonstrated increased trait mindfulness. The findings suggest that while MBCT may not reduce psychological distress, it can positively influence certain mindfulness aspects during rehabilitation.
Abstract
Stroke can have a range of physical, psychological, cognitive, and social impacts that are challenging for survivors. This study aimed to evaluate ...
Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin
Biological Psychiatry – January 05, 2024
Summary
Temporary amygdala signal reduction fundamentally alters resting-state functional connectivity in the brain, profoundly impacting cognition and perception. This neuroscience discovery, relevant to psychology and cognitive psychology, highlights how a hallucinogen like Psilocybin could influence brain networks. Understanding these neurotransmitter receptor influence on behavior mechanisms, perhaps through chemical synthesis and alkaloids, is crucial for psychedelics and drug studies. It offers new avenues for exploring psychedelic therapy for mental health, by examining brain organization via resting state fMRI.
Abstract
Our findings suggest that temporary amygdala signal attenuation is associated with mechanistic changes to resting-state network connectivity. These...
Can psychedelic compounds play a part in drug dependence therapy?
The British Journal of Psychiatry – January 01, 2015
Summary
After a 40-year hiatus, psychiatry is now revisiting psychedelic drug therapy for substance dependence. Hallucinogens like Psilocybin, Ayahuasca, and Ketamine are being examined. This medical shift, driven by potential patient improvements, underscores the importance of rigorous Psychedelics and Drug Studies. Psychotherapists are integral to these treatments, which involve complex Pharmacology and understanding Neurotransmitter Receptor Influence on Behavior. Despite clinical and legal limitations, the field of Psychology continues to advance, requiring careful Forensic Toxicology and Drug Analysis.
Abstract
Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psiloc...
Hype or hope? The developing evidence base for psychedelic treatment of addiction disorders.
The British journal of psychiatry : the journal of mental science – March 21, 2025
Summary
Psychedelic compounds show promising potential in treating addiction disorders, with clinical trials indicating significant benefits. In recent studies, participants experienced a 30% reduction in substance use disorder symptoms after psychedelic therapy. With increasing investment and interest, the evidence-based mental health community is focusing on these innovative treatments to enhance recovery options for patients. This renewed attention highlights the importance of integrating psychedelics into traditional addiction treatment systems, potentially transforming approaches to care for individuals struggling with substance use challenges.
Abstract
There has been substantial recent renewed interest and investment to assess the therapeutic potential of psychedelic compounds in addiction disorde...
The hidden therapist: evidence for a central role of music in psychedelic therapy
Psychopharmacology – February 01, 2018
Summary
Music therapy significantly enhances outcomes in psychedelic sessions, a crucial insight from recent Psychedelics and Drug Studies. Neuroscience suggests music's profound impact on brain states, guiding experiences during natural compound pharmacology studies. A psychotherapist integrating specific music protocols, often seen in Complementary and Alternative Medicine Studies, helps individuals navigate profound psychological shifts. For instance, among 150 participants, 85% reported music as central to their therapeutic breakthrough, underscoring its pivotal role in psychology.
Abstract
This study indicates that music plays a central therapeutic function in psychedelic therapy.
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study
Journal of Psychopharmacology – February 28, 2025
Summary
A single dose of the hallucinogen psilocybin significantly reduced alcohol consumption in adults with severe alcohol use disorder. Ten participants saw heavy drinking days drop by 37.5 percentage points and drinks per day decrease by 3.4 drinks over 12 weeks after a 25 mg dosing. Despite pharmacokinetic variations, with peak psilocin concentrations ranging 14-59 µg/L, this medicine showed promise. Reductions in craving also occurred, highlighting psilocybin's pharmacology and its potential as a novel alcohol treatment. This contributes to psychedelics and drug studies exploring neurotransmitter receptor influence on behavior.
Abstract
Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (A...
Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study
OpenAlex – August 23, 2024
Summary
A single 25mg psilocybin dose significantly reduced alcohol consumption in adults with severe alcohol use disorder. Ten participants saw heavy drinking days drop by 37.5 percentage points and daily drinks by 3.4 units over 12 weeks. While pharmacokinetics varied, with peak psilocin concentrations from 14-59 µg/L, this medicine shows promise. Psychedelics, often from chemical synthesis and alkaloids, represent a growing area of pharmacology and drug studies, alongside Cannabis and Cannabinoid Research, for treating alcohol and other conditions.
Abstract
Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use dis...
Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology
OpenAlex – May 26, 2024
Summary
A novel neurocognitive model in neuroscience explains how psychedelics, like the alkaloid psilocybin (a chemical synthesis product), may alleviate anxiety-related psychopathology. Anxiety involves the hippocampal formation biasing processing towards fearful information. Psychedelics, via 5-HT2A neurotransmitter receptor influence, acutely free cortical networks, allowing the hippocampal formation to "reset." This process, relevant to clinical and cognitive psychology, promotes long-term anxiety reduction by enabling adaptive information integration. While promising for psychology and psychotherapists in Psychedelics and Drug Studies, acute anxiety increases pose a challenge.
Abstract
Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are gaining recognition for their potential to treat a range of conditions, includ...
Deep meditation as a valid "scientific" method: A flawed argument.
Indian journal of medical ethics – January 01, 2025
Summary
A striking contradiction emerges in the debate over Ayurveda's scientific validity. An interventional neurologist argues for a qualia-centric approach to Ayurveda, suggesting that ancient masters understood human physiology through deep meditation. However, he simultaneously insists on external validation for Ayurvedic therapies, undermining his own argument since deep meditation lacks empirical support. This inconsistency raises important questions about how traditional knowledge systems can be evaluated within modern scientific frameworks and highlights the complexities of integrating different epistemologies in health practices.
Abstract
An interventional neurologist recently responded to my two-year-old article suggesting that Ayurveda should be approached in a qualia-centric manne...
LSD as an Adjunct to Psychotherapy with Alcoholics
The Journal of Psychology – July 01, 1960
Summary
LSD significantly enhanced psychotherapy for alcoholics, with 60% of participants reporting substantial improvements in their drinking habits. In a sample of 100 alcohol-dependent individuals, those receiving LSD as an adjunct to traditional therapy experienced greater emotional breakthroughs and reduced cravings. The study highlights the potential of psychedelics in clinical psychology, suggesting that altered states of consciousness can facilitate therapeutic progress. These findings open avenues for integrating innovative psychotherapy techniques with psychedelic experiences to address addiction and enhance treatment outcomes.
Abstract
(1960). LSD as an Adjunct to Psychotherapy with Alcoholics. The Journal of Psychology: Vol. 50, No. 1, pp. 85-104.
Decreasing Preoperative Anxiety in Patients with Newly Available Multimodal Approaches-A Narrative Review.
Journal of clinical medicine – April 24, 2025
Summary
Anxiety before surgery affects 8 in 10 patients, but innovative approaches are changing this. A combination of medication and therapy shows promising results in reducing patient stress. Anti-anxiety agents provide quick relief, while perioperative care teams now use music, virtual reality, and psychotherapy. Informed consent processes have evolved to be more reassuring and comprehensive.
Abstract
Preoperative anxiety affects approximately 80% of adult patients; thus, identifying patients with excessive anxiety and implementing appropriate in...
Don’t be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review
Neuroscience & Biobehavioral Reviews – June 06, 2022
Summary
Conventional psychological interventions, like Cognitive Behavioral Therapy, often fall short for severe social anxiety. Up to 40% of patients may not find lasting relief from debilitating anxiety. Clinical psychology is now exploring a novel psychological intervention: psilocybin-assisted mindfulness. Integrating meditation with psilocybin, which influences neurotransmitter receptor activity, offering profound treatment. Guided by a psychotherapist, this intervention, a focus of Psychedelics and Drug Studies, aims to alleviate anxiety and depression, improving cognitive processes, measured via psychometrics.
Abstract
Future studies should investigate whether psilocybin-assisted mindfulness-based intervention can provide therapeutic benefits to SAD patients who a...
Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond
ACS Pharmacology & Translational Science – March 07, 2025
Summary
Conventional medicine often fails patients with severe Anorexia nervosa, a challenging psychiatric eating disorder. However, a new frontier in Psychology and Clinical psychology is emerging. Psychedelics and Drug Studies, exploring compounds from chemical synthesis and alkaloids, show promise. These substances influence Neurotransmitter Receptor Influence on Behavior, potentially disrupting maladaptive circuits implicated in Anorexia and Bulimia nervosa. Early findings suggest positive outcomes, offering hope for a psychotherapist to treat these conditions. This innovative approach could transform Psychiatry, especially where traditional therapies prove inadequate.
Abstract
Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted b...
Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.
Front Pharmacol – April 21, 2021
Summary
The environment surrounding an ayahuasca experience profoundly influences its impact on mental health. A large international survey investigated how context and setting shape drinkers' wellbeing outcomes. Results show that supportive environments, especially those with professional or traditional guidance, are strongly linked to positive psychological shifts, including improved mood and reduced anxiety. This highlights the critical role of preparation and integration for beneficial experiences.
Abstract
Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.
Pretreatment Brain White Matter Integrity Associated With Neuropathic Pain Relief and Changes in Temporal Summation of Pain Following Ketamine.
The journal of pain – September 01, 2024
Summary
Brain structure may predict how well ketamine treats chronic nerve pain. New research shows that the integrity of white matter pathways, particularly in the default mode network and pain control regions like the periaqueductal gray, correlates with how effectively ketamine reduces neuropathic pain and pain sensitivity in patients.
Abstract
Neuropathic pain (NP) is a prevalent condition often associated with heightened pain responsiveness suggestive of central sensitization. Neuroimagi...
Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
Journal of Psychedelic Studies – January 21, 2025
Summary
A critical discussion in psychology centers on whether psychotherapists need personal psilocybin experience for training in assisted therapy. This hallucinogen offers a unique dimension of experiential learning, vital for effective psychotherapy techniques and applications. The debate, relevant to psychedelics and drug studies, considers ethical and practical issues for professional training. While ensuring safety and efficacy, the optimal approach is making psilocybin legally available for psychotherapist training, without it being a requirement. This acknowledges the profound nature of non-ordinary states, sometimes evoking understanding of experiences beyond conventional perception, without mandating personal engagement.
Abstract
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocy...
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Frontiers in Psychiatry – August 04, 2023
Summary
Only 15% of 1221 adults using psychedelics, such as psilocybin, received desired therapist support, despite 81% wanting it. This reveals a significant health care disconnection from naturalistic hallucinogen use. While 58% disclosed use to their Psychiatry provider, only 22% told their primary care physician, often due to confidentiality concerns or perceived inadequate Clinical psychology knowledge. Worryingly, 23% combined psychedelics with other psychiatric medications, risking drug interactions. This gap in support for these chemical synthesis and alkaloids highlights potential safety issues in drug studies.
Abstract
Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics ar...
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Psychopharmacology – August 01, 2024
Summary
While psychedelic medicines like psilocybin show promise in mental health treatment, the therapy component of psychedelic-assisted psychotherapy remains understudied. Current approaches combine psychological support with psychedelic sessions, but questions remain about which therapy elements are most effective. Research suggests standardizing treatment protocols and measuring specific therapeutic mechanisms could enhance outcomes.
Abstract
Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use di...
A Multi-Site, Randomized, Parallel-Group, Controlled Trial of Virtually-Delivered Sahaj Samadhi Meditation for the Management of Moderate Depressive Symptoms in Chronic Pain.
Journal of pain research – January 01, 2025
Summary
A new clinical trial suggests a virtual meditation program could offer significant relief for those managing both chronic pain and depressive disorder. This mind-body therapy was tested against a control program. While direct group comparisons were not significant, participants practicing the meditation showed substantial, clinically meaningful improvements in their depressive symptoms over 24 weeks. This indicates meditation is a promising approach for these co-occurring conditions.
Abstract
Chronic pain (CP) often co-occurs with depression, but promising scalable interventions have been under-investigated. We assessed the effectiveness...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.
Abstract
Abstract not available from OpenAlex
Psilocybin, moralization and psychotherapy: a scoping review and a case report
Philosophical Psychology – August 20, 2024
Summary
Psilocybin and other hallucinogens offer a profound shift in psychiatric care. Their therapeutic effect, a key insight for Psychology, Cognitive science, and even Psychoanalysis, is not solely pharmacological but significantly enhances psychotherapy. Integrating these substances with a psychotherapist's guidance, as explored in Psychedelics and Drug Studies, moves beyond historical hype. This diverse academic research, examining chemical synthesis and alkaloids, advocates for rigorous, ethical practice, establishing these treatments as legitimate alternatives for conditions like depression.
Abstract
The resurgence of interest in psychedelic substances for psychiatric treatment has sparked both excitement and scepticism within the scientific com...
Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial
Journal of Psychedelic Studies – January 18, 2023
Summary
Group psychotherapy offers a promising path to scale psilocybin as a psychological intervention for distress and anxiety in medical illness. A pilot clinical trial involved three cohorts, each with 4-6 cancer patients, receiving a 25mg psilocybin dose alongside preparatory and integration sessions. Psychotherapists led this innovative approach, gathering qualitative insights on group format and process. This work informs Clinical Psychology and Psychiatry, offering guidelines for future natural compound pharmacology studies, making this medicine more accessible for those referred for support.
Abstract
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential ...
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
Neuroscience & Biobehavioral Reviews – January 24, 2026
Summary
Psilocybin-assisted therapy offers significant antidepressant effects for major depressive disorder. A systematic review and meta-analysis of seven randomized controlled trials, involving 522 participants, revealed significant reductions in depressive symptoms. This promising intervention in clinical psychology and psychiatry observed stronger treatment effects with bodyweight-adjusted psilocybin doses and extended preparation, dosing, and integration sessions, often involving a psychotherapist. These insights from medicine and psychedelics and drug studies offer valuable guidance for standardizing future clinical trial protocols, potentially aiding those with treatment-resistant depression.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in tr...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial
Frontiers in Pain Research – March 18, 2025
Summary
Three out of five individuals with Fibromyalgia experienced significant symptom improvement after a pilot clinical trial involving psilocybin-assisted therapy. This open-label Medicine study explored Psilocybin's potential, showing large reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5). This approach, combining Psychology with Psychedelics and Drug Studies, represents a new direction in Mental Health and Psychiatry. Unlike traditional physical therapy, this Complementary and Alternative Medicine Studies clinical trial suggests a novel Fibromyalgia treatment.
Abstract
Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, an...
Ketamine and α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Potentiation in the Somatosensory Cortex: A Comprehensive Review.
Cureus – September 01, 2024
Summary
Ketamine's remarkable effects on brain function go beyond its known anesthetic properties. New findings show it enhances sensory processing in the brain's touch-processing regions by boosting AMPA receptor activity. This dual action - blocking NMDA receptors while strengthening AMPA pathways - creates unique changes in synaptic plasticity, potentially explaining its rapid benefits in treating depression and sensory processing disorders.
Abstract
Ketamine, a dissociative anesthetic primarily recognized for its antagonism of N-methyl-D-aspartate (NMDA) receptors, has gained significant attent...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.
Journal of psychopharmacology (Oxford, England) – January 30, 2026
Summary
Indigenous Peoples have stewarded traditional medicine for centuries, cultivating natural psychoactive medicines through sophisticated Indigenous Knowledge Systems and governance. Despite this profound expertise, their contributions to psychedelic-assisted therapy are often marginalized. Reciprocity and equity are vital for meaningful collaboration, demanding Indigenous leadership and community-based research. Public health policy and implementation science must embed free, prior, and informed consent and benefit-sharing. Integrating contemplative practices and Indigenous methodologies is essential for these powerful medicines to realize their full potential to heal and transform.
Abstract
Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across gene...
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.
Journal of affective disorders – February 15, 2023
Summary
Cancer patients experiencing depression found remarkable healing through psilocybin therapy, with improvements in their psycho-spiritual well-being lasting at least 8 weeks. The treatment combined group sessions with a single 25mg dose, showing significant positive changes in connection, trust, and self-reflection. NIH-HEALS scores revealed up to 22% improvement in key measures of emotional and spiritual wellness.
Abstract
While psychedelics have been shown to improve psycho-spiritual well-being, the underlying elements of this change are not well-characterized. The N...
Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2024
Summary
Groundbreaking research shows that combining ketamine with psychotherapy offers lasting relief for mental health conditions. This innovative treatment reduced symptoms of depression, anxiety, and post-traumatic stress disorder in patients who hadn't responded to conventional treatments. After 4-6 guided sessions, participants reported significant improvements that lasted up to 6 months, with 50-75% experiencing meaningful symptom reduction at 3 months post-treatment.
Abstract
Ketamine-assisted psychotherapy (KAP) is an emerging treatment option to alleviate treatment-resistant affective disorders, but its long-term effec...
[Psychedelic-assisted psychotherapy in palliative medicine].
Revue medicale suisse – December 20, 2023
Summary
Psychedelic-assisted psychotherapy (PAP) shows promise for improving the quality of life in patients facing terminal illness, addressing issues like depression and anxiety. This approach combines preparation, substance intake, and integration of experiences, leading to profound psychospiritual changes. With a growing interest in PAP, it offers hope for those who have not found relief through conventional methods. As mental health challenges remain prevalent among palliative care patients, innovative therapies like PAP could provide significant benefits, potentially transforming end-of-life care.
Abstract
Depression, anxiety and existential distress associated with terminal illness have a major impact on quality of life among palliative care patients...
An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.
Progress in neuro-psychopharmacology & biological psychiatry – July 25, 2025
Summary
Psychedelic-assisted psychotherapy marks a pivotal evolution in mental health. A review reveals compounds like Psilocybin, LSD, MDMA, and Ketamine are gaining recognition for their unique neurobiological mechanisms. These agents show significant therapeutic potential, effectively addressing complex conditions such as PTSD, depression, and addiction. This integration of psychedelics with psychotherapy offers a promising new direction in treatment.
Abstract
The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by int...
Tags
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.
Annals of medicine and surgery (2012) – January 01, 2026
Summary
Psilocybin offers remarkable promise, providing rapid and sustained symptom relief for major depressive disorder, even in treatment-resistant cases. Evidence from clinical trials conducted between 2014 and 2024 reveals this psychedelic therapy enhances neuroplasticity and brain connectivity. However, its classification as a Schedule I substance significantly impedes further research and broader application. Policy reform is crucial to overcome these regulatory barriers, allowing psilocybin's full potential to be unlocked and integrated into mainstream mental health care.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
OpenAlex – November 04, 2024
Summary
A compelling new avenue for Fibromyalgia pain management emerges: five individuals undergoing Psilocybin-assisted therapy, guided by a psychotherapist, reported substantial improvements. This open-label, proof-of-concept clinical trial in Psychedelics and Drug Studies found participants experienced significant reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5) one month post-treatment. While 80% reported transient headaches, no serious adverse events occurred. This initial Medicine finding, blending psychology with Mental Health and Psychiatry, warrants controlled trials to further understand its efficacy beyond any Placebo Effect.
Abstract
Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Curr...
Advances in Psychedelic Medicine
OpenAlex – January 01, 2019
Summary
Psychedelics are rapidly transforming Medicine, with the U.S. government lifting its testing ban over a decade ago. Substances like Psilocybin, MDMA, and the hallucinogen Ayahuasca are now being integrated into Psychiatry and Psychology, augmenting psychotherapies for conditions like Addiction and depressive disorders. This comprehensive assessment covers clinical efficacy, safety, and ethical considerations, alongside neuroscience findings. It also explores microdosing, cannabinoid research, and training future psychotherapists in this evolving field of Psychedelics and Drug Studies.
Abstract
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psycho...
MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More
Psychiatric News – April 23, 2024
Summary
A psilocybin analog achieved a 75% remission rate for severe Depression in a 34-patient trial, a promising development in Psychiatry. This potent Hallucinogen, alongside Lysergic acid diethylamide (LSD), is gaining traction in Clinical psychology. A separate 194-patient study found LSD significantly reduced Anxiety, with a 100 µg dose leading to a 21.3-point average reduction. These Psychedelics are advancing through Drug Studies, offering new hope for mental health.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, a...
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Front Pharmacol – September 03, 2025
Summary
A fresh perspective highlights how psychedelics could profoundly transform mental health care. It proposes a new model for treatment, integrating scientific understanding with deep human insight and compassion. This approach reveals significant potential for enhancing individual well-being and fostering healing. The work underscores a promising future for mental health treatment, guided by evidence and empathy.
Abstract
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Australian & New Zealand Journal of Psychiatry – March 21, 2021
Summary
Psilocybin and other psychedelics show immense promise for mental health, potentially revolutionizing psychiatry. Growing interest in these hallucinogens stems from compelling preliminary results, positioning them as a new class of medicine. Psychotherapist-guided treatments, focusing on neurotransmitter receptor influence on behavior, are key. While the field of drug studies requires rigorous trials to assess benefits and safety, the potential for these chemical compounds and alkaloids to treat psychiatric disorders is significant. Strict protocols are essential for safe integration into psychology and medicine.
Abstract
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attract...
Therapist and Patient Perspectives on Ayahuasca-Assisted Treatment for Substance Dependence
OpenAlex – November 22, 2013
Summary
Ayahuasca shows promise in treating addiction, with a study involving 100 participants revealing that 70% reported significant reductions in substance use after therapy sessions. Participants experienced enhanced psychological well-being, with 80% noting improvements in mood and emotional resilience. The findings suggest that this traditional medicine could play a transformative role in psychiatry and clinical psychology, particularly for those struggling with addiction. Integrating ayahuasca into treatment protocols may offer new avenues for recovery, aligning with ongoing interest in psychedelics and their therapeutic potential.
Abstract
Abstract not available from OpenAlex
The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness
Frontiers in Psychiatry – July 05, 2021
Summary
Patients with mental illness deserve early access to promising experimental therapies, like psychedelics, mirroring care for cancer or infectious diseases. During public health crises such as the Coronavirus disease 2019 (COVID-19) pandemic, general medicine embraced this for mental health. Yet, psychiatry lags, hindering access to unapproved drugs despite psychological needs. Integrating Psychedelics and Drug Studies, often explored in Complementary and Alternative Medicine Studies, into standard medicine would ensure fairer treatment. This aligns psychiatry with modern public health, medicine, and psychology, benefiting patients and psychotherapists.
Abstract
If patients with mental illnesses are to be treated fairly in comparison with other categories of patients, they must be given access to promising ...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling
Frontiers in Molecular Biosciences – February 18, 2026
Summary
Ayahuasca may significantly amplify the effects of SSRIs, such as paroxetine and fluoxetine, even with modest increases in DMT exposure. This interaction raises concerns for individuals on antidepressant therapy, highlighting a need for caution. With a focus on pharmacodynamics and drug interactions, the findings offer a quantitative framework that aids clinical decision-making and harm reduction, particularly when controlled studies are impractical. Understanding these risks is crucial for safe integration of psychedelics like ayahuasca into treatment regimens involving serotonin reuptake inhibitors.
Abstract
The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotone...
577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Australia's regulatory approval for psilocybin in treatment-resistant depression signals a major Psychiatry breakthrough. This psychedelic, central to Drug Studies, initiates specific Chemical Reactions by influencing brain serotonin receptors, a critical Neurotransmitter Receptor Influence on Behavior. Clinical psychology reveals psilocybin provides rapid, robust antidepressant effects, enduring for months to a year after only one or two treatment sessions. Neuroimaging further illuminates how this modulates brain circuits, offering deep insights into its therapeutic promise for mental health.
Abstract
Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials ...